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The carboxyl-terminal fibrin-binding domain, Fib2, 
of human fibronectin was expressed in mouse L cells 
as a fusion protein with the signal sequence of human 
protein C inhibitor. The recombinant Fib2 (rFib2) pro- 
tein synthesized by transfected cells retained the abil- 
ity to form dimers with each other or with mouse 
fibronectin subunits and was secreted to the medium 
after extensive glycosylation. Only a small fraction of 
the secreted protein was incorporated into the pericel- 
lular matrix. Interestingly, the secreted rFib2 protein 
displayed a remarkable heterogeneity upon sodium do- 
decyl sulfate-polyacrylamide gel electrophoresis, giv- 
ing rise to a broad band corresponding to M, of 60,000- 
90,000. The heterogeneity was eliminated mostly by 
treatment with neuraminidase and further by treat- 
ment with endo-cY-N-acetylgalactosaminidase. Treat- 
ment with peptide:N-glycosidase F did not alter the 
heterogeneity of the protein, indicating that differen- 
tial sialylation of O-linked, but not N-linked, glycans 
is largely responsible for the apparent heterogeneity. 
The presence of O-linked but absence of N-linked gly- 
cans was further supported by the observations that 
peanut agglutinin specifically bound to the desialylated 
rFib2 protein, whereas neither concanavalin A nor 
lentil lectin bound to the protein irrespective of prior 
neuraminidase treatment. Since the apparent hetero- 
geneity of the rFib2 protein was only observable with 
the secreted, but not the cytoplasmic form, sialylation 
of O-linked glycans may be essential for, or regulate 
as a rate-limiting step, the transit of the recombinant 
protein to the extracellular space. 
Fibronectin (FN)’ is a cell adhesive protein present in the 
extracellular matrix and various body fluids. FN has been 
implicated in diverse biological processes accompanying cell 
adhesion and migration on the extracellular matrix, such as 
embryonic development, wound healing, hemostasis and 
thrombosis, and tumor metastasis (for reviews, see Refs. l- 
4). Oncogenic transformation of cells usually results in a 
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marked decrease of FN associated with cell periphery (5, 6). 
FN is synthesized by fibroblasts and other cell types as a 
dimer of identical or nonidentical subunits with M, of about 
250,000. Although FN is encoded by a single gene, differential 
splicing of the primary transcript at three specific regions 
results in as many as 20 different isoforms having slightly 
different amino acid sequences (7-13). FN has a characteristic 
modular structure; it consists of three homologous repeats, 
termed types I, II, and III (14). These repeats are assembled 
into a series of structural domains, each having distinct bind- 
ing activities toward collagens, sulfated glycosaminoglycans, 
fibrin, and cell surface receptors collectively termed integrins 
(2, 15-17). 
Despite extensive characterization of each functional do- 
main, little has been understood about the significance of the 
functional cooperativity among these domains. This is mainly 
because the conventional methodology employed in previous 
studies, i.e. proteolytic dissection of the intact protein fol- 
lowed by isolation and characterization of each domain, could 
not address the functional cooperativity among distally lo- 
cated domains. Thus, an alternative approach has been sought 
(18). Using the recombinant DNA technique one can express 
essentially any combination of the domains as a single poly- 
peptide and evaluate the significance of their functional coop- 
erativity. 
As a first step toward this goal, we constructed a recombi- 
nant cDNA to express the carboxyl-terminal fibrin-binding 
domain, Fib2, of human FN in cultured mouse cells as a fusion 
protein with the signal sequence of human protein C inhibitor. 
The recombinant Fib2 (rFib2) protein thus expressed was 
capable of forming dimers with each other or with endogenous 
mouse FN subunits and secreted to the medium after an 
extensive O-linked glycosylation. 
EXPERIMENTAL PROCEDURES 
Materials-DNA modifying and restriction enzymes were obtained 
from Takara Shuzo (Kyoto, Japan). [35S]Methionine, GeneScreen 
Plus, and a DNA random primer extension kit were purchased from 
Du Pont-New England Nuclear, [#P]dCTP from Amersham Japan 
(Tokyo, Japan), and G418 (Geneticin), N-tosyl-L-phenylalanine chlo- 
romethyl ketone-treated trypsin, thermolysin from Sigma. Endo-ol- 
N-acetylgalactosaminidase from Alcarigenes sp. was obtained from 
Seikagaku Kogyo (Tokyo, Japan), neuraminidase from Arthrobactor 
ureufuciens was from Nacalai Tesque (Kyoto, Japan), and peptide:N- 
glycosidase F from Flavobacterium meningosepticum from Boehringer 
Mannheim Yamanouchi (Tokyo, Japan). Peroxidase-conjugated lec- 
tins were purchased from Seikagaku Kogyo. The eukaryotic expres- 
sion vector pBactCAT9 and pKOneo were kindly provided by Dr. 
Norman Davidson (California Institute of Technology, Pasadena, 
CA) and Dr. Allen Senear (Fred Hutchinson Cancer Research Center, 
Seattle, WA), respectively. The cDNA encoding the signal sequence 
of human protein-C inhibitor, PCI-GmplO, was a generous gift-of Dr. 
Koji Suzuki (Institute for Enzyme Research, University of Toku- 
shima, Tokushima, Japan). Monoclonal antibodies FN9-1 and FN8- 























402 Expression of a Recombinant Fibronectin Domain in Mouse Cells 
generous gifts of Masahiko Katayama (Takara Shuzo Co., Ltd.). 
Fluorescein-conjugated goat anti-rabbit IgG and rhodamine-conju- 
gated goat anti-mouse IgG were obtained from Cappel Worthington 
Biochemicals (Malvern, PA). 
Cells and Cell Culture-Mouse L cells were kindly provided by Dr. 
Masahiro Ishiura (National Institute for Basic Biology, Okazaki, 
Japan) and SV40-transformed human fibroblasts WI-38VA13 were 
from Dr. Hiroshi Mizusawa (Japanese Cancer Research Resources 
Bank, Tokyo, Japan). Cells were grown in Dulbecco’s modified Eagle’s 
medium containing 10% fetal bovine serum (GIBCO). 
DNA Constructions-The cDNA clone pHCF22 encoding the en- 
tire IIICS region of human FN was prepared by oligonucleotide- 
primed cDNA synthesis (19) using the poly(A)+ RNA isolated from 
SV40-transformed human fibroblast WI-38VA13 as a template. The 
699-base pair SacI-ApaI fragment of pHCF22 and the 1429-base pair 
ApaI-Hind111 fragment of pLF2 (9) were cloned together into the 
SacI/HindIII-cleaved pUC118, yielding the plasmid pHCF2D which 
encodes the entire IIICS region and the Fib2 domain. 
A plasmid vector pAISF21 for the expression of the human Fib2 
domain was constructed by replacing the chloramphenicol acetyl- 
transferase gene of pBactCAT9 (20) with the cDNAs encoding the 
signal sequence of human protein C inhibitor, a putative N-linked 
glycosylation site, and the Fib2 domain (see also Fig. 1). A 127-base 
pair fragment of the cDNA PCI-6mplO encoding the signal sequence 
of human protein C inhibitor was excised by double digestion with 
Hind111 and SmaI, subcloned in the HindIII/SmaI-cleaved pUCI9, 
and isolated as a HindIII-EcoRI fragment. The cDNA sequence 
encoding a putative N-linked glycosylation site of human FN was 
isolated from pLF5 (9) as a 170-base pair EcoRI-PuuII fragment (see 
Fig. l), subcloned into pUC18, and isolated as a EcoRI-BamHI 
fragment. The cDNA encoding most of the IIICS region and its 
downstream amino acid sequence of human FN was excised from 
pHCF2D as a 1591-base pair BglII-ScaI fragment. These three frag- 
ments were ligated in tandem with the HindIII/HpnI-cleaved 
pBactCAT9, yielding the Fib2 expression vector pAISF21. 
DNA Transfection and Selection of Stable Transformants-Mouse 
L cells were used as the recipient for DNA transfection. Transfection 
of cells was performed using the calcium phosphate precipitation 
technique as described by Chen and Okayama (21). Calcium phos- 
phate-DNA solution containing 10 ng of pAISF21 and 1 pg of pKOneo 
was used to transfect 2 x lo5 cells grown in a 6-cm dish. Stably 
transformed cells were selected in the growth medium containing 0.8 
mg/ml of G418. Routinely, several hundred colonies of transformants 
were obtained per transfection. Randomly selected colonies were 
individually expanded, assayed for the expression of the recombinant 
Fib2 mRNA by Northern blot analysis (19), and the isolate expressing 
the highest level of the mRNA was subjected to the second round of 
cloning by the limiting dilution method. 
Northern Blot Analysis-RNAs were extracted from cells by the 
guanidine/CsCl method (22). After glyoxalation, RNAs were sepa- 
rated by electrophoresis on a 1% agarose gel and transferred to a 
GeneScreen Plus membrane. The membrane was then hybridized 
with the 32P-labeled probe DNA prepared by the random primer 
extension method (23). 
Pulse-Chose Experiments and Immune Precipitation-Cells grown 
to confluence in a 6-cm culture dish were preincubated in methionine- 
free minimum essential medium for 1 h, then pulse-labeled with [3”S] 
methionine at 50 &i/ml for 1 h. After labeling, unlabeled methionine 
was added to the medium at 30 pg/ml for chase. At indicated time 
points, the medium was harvested, clarified by centrifugation at 
10,000 x g, and incubated with monoclonal anti-human FN antibody 
immobilized on Sepharose CL4B. The cell layers were rinsed with 
phosphate-buffered saline, and scraped off in 20 mM Tris/HCl (pH 
7.6) containing 2% sodium deoxycholate, 2 mM EDTA, and 1 mM 
phenylmethylsulfonyl fluoride. The cell lysate was homogenized by 
repeated passages through a 27-gauge needle and incubated with the 
monoclonal antibody immobilized on Sepharose beads overnight at 
4 “C. The beads were washed three times with phosphate-buffered 
saline and then boiled in the sample treatment buffer containing 2% 
SDS and 5% 2-mercaptoethanol. The solubilized proteins were ana- 
lyzed by SDS-PAGE and subsequent fluorography (24). The relative 
radioactivity associated with protein bands of interest was quantified 
with a Fujix Bio-Image Analyzer BAlOO using an erasable phosphor 
imaging plate (25). 
Indirect Zmmunofluorescence Staining-Cells were grown on cover- 
slips to confluence and immunostained with either polyclonal or 
monoclonal anti-human FN antibodies at appropriate dilutions with- 
out fixation. The secondary antibodies used were fluorescein-conju- 
gated goat anti-rabbit IgG and rhodamine-conjugated goat anti-mouse 
IgG, respectively. The immunostained cells were fixed with 3% par- 
aformaldehyde and examined with a Zeiss epifluorescence microscope 
Axiophot and photographed on Kodak Tri-X films. 
Zsolation of the Recombinant Fib2 (rFib2) Protein-The rFib2 pro- 
tein secreted by stable transformants were isolated from conditioned 
medium by immunoaffinity chromatography using monoclonal anti- 
body FNS-12 immobilized on Sepharose CL4B. All manipulations 
were conducted at 4 “C. The conditioned medium was harvested and 
clarified by centrifugation at 1700 x g at 4 ‘C. The supernatant was 
supplemented with EDTA (5 mM) and phenylmethylsulfonyl fluoride 
(1 mM) and then applied to the antibody column (bed volume, 2 ml). 
The column was washed with phosphate-buffered saline and the 
bound proteins were eluted with 0.2 M glycine/HCl buffer (pH 2.8), 
dialyzed against 2 mM CAPS buffer (pH 10.5) containing 0.5 mM 
EDTA, and lyophilized. 
Enzyme Digestion of the rFib2 Protein-Limited proteolysis of the 
rFib2 protein with trypsin and thermolysin was carried out as de- 
scribed previously (26). Treatment with glycosidases was performed 
as follows: the recombinant protein (20 gg) was treated with (a) 50 
milliunits of neuraminidase in 0.1 M sodium acetate buffer (pH 5.0) 
at 37 ‘C for 4 h, (b) 0.5 milliunits of peptide:N-glycosidase F in 50 
mM Tris/HCl (pH 9.0) containing 20 mM 2-mercaptoethanol, 10 mM 
EDTA, 0.5% SDS, and 0.85% Triton X-100, at 37 “C for 60 h, or (c) 
10 milliunits of endo-a-N-acetylgalactosaminidase in 50 mM sodium 
citrate (pH 4.2) containing 1 mM EDTA at 37 “C for 15 min. In some 
experiments, the rFib2 protein was first treated with neuraminidase, 
dialyzed against water, and then digested with peptide:N-glycosidase 
F or endo-a-N-acetylgalactosaminidase under the conditions speci- 
fied above. 
SDS-PAGE, Zmmunoblotting, and Lectin Blotting-SDS-PAGE 
was performed as described by Laemmli (27). Proteins separated on 
the gels were transferred to nitrocellulose membrane (28) and then 
stained with antibodies as described (29) or with peroxidase-lectin 
conjugates as described by Kijimoto-Ochiai et al. (30). The bound 
peroxidase-lectin conjugates were visualized with 4-chloro-1-naphtol. 
RESULTS 
Isolation of Stable Transformants Expressing the rFib2 Pro- 
tein-The plasmid pAISF21 was constructed to express in the 
mouse L cells the entire carboxyl-terminal Fib2 domain of 
human FN, including most of the preceding IIICS region, as 
a fusion protein with the signal sequence of human protein C 
inhibitor (Fig. 1). A short cDNA sequence encoding a putative 
N-linked glycosylation site in the cell-binding domain was 
inserted in frame between those encoding the signal sequence 
and the Fib2 domain. The expression of the recombinant 
cDNA was driven by chicken fi-actin promoter in conjunction 
FlBRONECTlN PCLYPEPTIDE. 
FIERCNECTIN cDNA. 
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FIG. 1. Construction of the Fib2 expression vector 
pAISF21. A model for polypeptide structure of human FN as well 
as the corresponding cDNA restriction map are diagrammed above 
the plasmid construction. Closed and open circles shown in the model 
for the polypeptide structure represent the putative sites for N- and 
O-linked glycosylation (31), respectively. Abbreviations used for the 
restriction sites are: A, ApaI; G, BgZII; H, HindIII; Pu, PuuII; R, 
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with SV40 polyadenylation signal (20). 
Cotransfection of 2 x lo” L cells with pAISF21 and pKOneo 
and subsequent selection with G418 yielded several hundred 
colonies of stable transformants. Among those randomly 
picked up and expanded, the transformant expressing the 
highest level of the rFib2 mRNA was selected by Northern 
blot analysis and subjected to the second round of cloning by 
limiting dilution, resulting in the isolation of the stable trans- 
formant L/201. Northern blot analysis demonstrated that a 
2.1.kilobase rFib2 mRNA was expressed in L/201 cells (Fig. 
2, lane 1) but not in another G418resistant clone L/205 (Fig. 
2, lane 2). The size of the rFib2 mRNA was in good agreement 
with that expected from the nucleotide sequence of the cDNA 
insert. Southern hybridization analysis indicated that multi- 
ple copies of pAISF21 were integrated per haploid DNA in 
the clone L/201, whereas the clone L/205 contained a single 
integrated copy of the plasmid (data not shown). 
Synthesis and Secretion of the rFib2 Protein by L/201 
Cells-In order to examine whether L/201 cells synthesize 
and secrete the rFib2 protein, the cells were pulse-labeled with 
[““S]methionine and the appearance of the rFib2 protein in 
the cytoplasm and in the medium was followed by immuno- 
precipitation with monoclonal anti-human Fib2 antibody 
FN8-12 immobilized on Sepharose CL4B (Fig. 3). After 2 h 
of chase, three proteins with apparent M, of 66,000, 54,000, 
and 51,000 were immunoprecipitated from the detergent ly- 
sate of the cells (Fig. 3B, lane 2), whereas heterogeneous 
proteins migrating at 60-90-kDa region on the gel were pre- 
cipitated from the conditioned medium (Fig. 3B, lane 4). 
Control antibody FN9-1, which is directed to the amino- 
terminal domain of human FN, did not immunoprecipitate 
these proteins either from the cell lysate or from the medium 
(Fig. 3B, lanes 1 and 3). None of these proteins were precipi- 
tated from the detergent lysate of the nonexpressor L/205 
with FN8-12 (Fig. 3A, lanes 2 and 4), confirming the specific- 
ity of the immunoprecipitation with this antibody. Since the 
molecular mass of the rFib2 protein calculated from the cDNA 
sequence is 49 kDa after removal of the signal sequence, these 
proteins immunoprecipitable with FN8-12 are likely to be 
differentially glycosylated forms of the rFib2 protein. The 
significant difference in the electrophoretic mobility between 
the rFib2 proteins precipitated from the cell lysate and from 
the medium is likely due to the sialylation of O-linked glycans 
occurring during secretion of the recombinant protein (see 
below). 
It should be noted that, besides these proteins, the endog- 
a -28s 
1 2 3 
FE. 2. Northern blot analysis of the rFib2 mRNA. Total 
RNA from stable transformants (20 pg) and from human fibroblast 
WI-38VA13 (5 pg) was hybridized with a l.2-kilobase human FN 
cDNA encoding the Fib2 domain. Lane I, RNA from L/201; lane 2, 
RNA from L/205; lane 3, RNA from WI-38VA13. 
Mr A 





FIG. 3. Pulse-chase analysis of the rFib2 protein expressed 
in transformed L cells. L/205 (A) and L/201 (B-D) cells were 
pulse-labeled with [““S]methionine and then chased with nonlabeled 
methionine as described under “Experimental Procedures.” After 2 h 
(A and B), 7 h (C), and 24 h (D) of chase, the radiolabeled rFib2 
protein was immunoprecipitated from the detergent lysate of the cells 
(lanes 1 and 2) or from the conditioned medium (lanes 3 and 4) with 
monoclonal antibody FN9-1 (lanes I and 3) or FNS-12 (lanes 2 and 
4). The positions of the cell-associated form (arrowheads) and se- 
creted form (brackets) of the rFib2 proteins are indicated. Shown in 
the left margin are the positions of the molecular weight standards. 
CHASE 
FIG. 4. Transit of the pulse-labeled rFib2 protein. The per- 
centages of the cell-associated (hatched column) and secreted (open 
column) rFib2 proteins after the indicated periods of chase were 
determined by quantifying the radioactivities associated with the 
51-, 54-, and 66-kDa (cell-associated) and 60-90-kDa (secreted) pro- 
tein bands marked in the Fig. 3. 
enous mouse FN was also immunoprecipitated with FN8-12 
(Fig. 3B, lanes 2 and 4). This is mainly due to the presence of 
the heterodimer consisting of the rFib2 protein linked to 
mouse FN subunits (see below), although mouse FN alone 
appears to cross-react weakly with FN8-12 and FN9-1 (Fig. 
3A, lanes 3 and 4). 
Quantitation of the relative radioactivity associated with 
the rFib2 proteins recovered from the cell lysate and from the 
medium indicated that nearly 70% of the pulse-labeled rFib2 
protein was recovered in the cell lysate and 30% in the 
medium after 2 h of the chase (Figs. 3B and 4). With increas- 
ing the chase period, the relative amounts of the cell-associ- 
ated 51-, 54-, and 66-kDa proteins versus those of the extra- 
cellular 60-90-kDa proteins decreased rapidly (Fig. 3, C and 
D), indicating that those proteins in the cell lysate represent 
the cytoplasmic form of the rFib2 protein. After 24 h of the 
chase, more than 95% of the pulse-labeled rFib2 protein was 
secreted to the medium (Fig. 4). 
Although most, if not all, of the rFib2 protein synthesized 
by L/201 cells was secreted to the medium, a small fraction 
of the protein became incorporated in the pericellular matrix 
upon prolonged cell culture. Indirect immunofluorescence 
staining with monoclonal anti-human FN antibodies demon- 
strated that the matrix of confluent L/201 cells was weakly 
immunostained with FN8-12 (Fig. 5A), although the matrix 
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NONREDUCED REDUCED 
FIG. 5. Indirect immunofluorescence staining of trans- 
formed L cells. Confluent monolavers of L/201 (A. C. and E) and 
L/205 (R, D, and F) cells were stained with monoclonal antibodies 
FN8-12 (A and B) and FN9-1 (C and D) or with polyclonal anti- 
human FN antibodies. 
nor L/205 cells was stained by immunofluorescence with the 
control antibody FN 9-l (Fig. 5, C and D), although both 
matrices were strongly stained with polyclonal anti-human 
FN antibodies which cross-react with mouse FNs (Fig. 5, E 
and F). 
Characterization of the rFib2 Protein Secreted to the Me- 
dium-The rFib2 protein secreted to the conditioned medium 
was isolated by immunoaffinity chromatography for further 
biochemical characterization. SDS-PAGE of the purified 
rFib2 protein under nonreducing conditions followed by im- 
munoblot analysis with FN8-12 identified three forms of the 
rFib2 protein (Fig. 6, left, lane 4): one form migrated at the 
position between the monomer and dimer of intact mouse FN, 
indicating that it represents the heterodimer of the rFib2 
protein linked to an intact mouse FN subunit. Other two 
forms of the rFib2 protein gave broad bands corresponding to 
M, of lOO,OOO-160,000 and 60,000-90,000. These forms are 
likely to represent homodimers and monomers of the rFib2 
protein, respectively. Upon reduction with 2-mercapto- 
ethanol, the rFib2 protein gave only the band corresponding 
to the monomer (Fig. 6, right, lane 4). Quantitation of the 
relative radioactivities of these three forms identified under 
nonreducing conditions indicate that the heterodimer, hom- 
odimer, and monomer comprise 26, 44, and 30%, respectively, 
of the total rFib2 protein secreted to the medium. These 
results indicate that the rFib2 protein retains the ability to 
recognize each other for specific dimerization of FN subunits. 
Evidence that the heterogeneous 60-90-kDa proteins are 
indeed the secreted form of the rFib2 protein was also ob- 
tained by limited proteolysis with trypsin or thermolysin. 
Based on our previous studies (15, 26, 29), the Fib2 domain 
of the recombinant protein is expected to yield 43- and 22- 
kDa fragments upon trypsin and thermolysin digestion, re- 
spectively (Fig. 7A). A mild trypsin digestion of human cel- 
lular FN released the Fib2 domain as 43- and 37-kDa frag- 
ments (Fig. 7B, center, lane 2), of which only the former 
fragment contained the alternatively spliced IIICS/A2 peptide 
segment (Fig. 7B, right, lane 2). Trypsin digestion of the 
(FN)*- q @ 
FN- “ 




FIG. 6. Immunoblot analysis of the purified rFib2 protein. 
The purified rFib2 protein was analyzed by SDS-PAGE under the 
reducing (right) or nonreducing (left) condition followed by immu- 
noblotting with FNS-12. Proteins transferred to nitrocellulose mem- 
brane were first stained with fast green (lanes 1 and 2) and then 
immunostained with FN8-12 (lanes 3 and 4). Lanes I and 3, human 
plasma FN (5 pg); lanes 2 and 4, the purified rFibP protein (5 pg). 
The positions of the heterodimer (arrow), homodimer (open arrow- 
head), and monomer (closed arrowhead) of the rFib2 protein are 
indicated in the margin. 
purified rFib2 protein, however, yielded only the 43-kDa frag- 
ment immunoreactive with both FN8-12 (Fig. 7B, center, lane 
5) and anti-IIICS/As antibodies (Fig. 7B, right, lane 5), being 
consistent with the presence of the IIICS/A, sequence within 
the recombinant protein. Furthermore, the Fib2 domain of 
the purified protein was released with thermolysin as a 22- 
kDa fragment (Fig. 7B, center, lane 6), as was the case with 
intact cellular FN (Fig. 7B, center, lane 3). It should be also 
noted that both the 43-kDa tryptic and 22-kDa thermolysin 
fragments derived from the rFib2 protein gave apparently 
homogeneous bands upon SDS-PAGE. These results indicate 
that the apparent heterogeneity of the secreted form of the 
rFib2 protein would arise from posttranslational modifica- 
tion(s) occurring at either the amino- or carboxyl-terminal 
flanking region of the Fib2 domain. 
A likely candidate for such modifications is glycosylation, 
since the rFib2 protein contains two putative sites for N- 
glycosylation and six sites for 0-glycosylation (31), most of 
which could be removed by a mild trypsin digestion (see Fig. 
7A). In order to examine this possibility, the purified rFib2 
protein was treated with various exo- and/or endoglycosidases 
(Fig. 8). Treatment with neuraminidase resulted in a marked 
reduction of the apparent molecular mass of the protein, 
yielding a less heterogeneous band migrating at n/i, of 58,000 
(Fig. 8, lane 2). It is unlikely that sialic acid residues removed 
by neuraminidase are derived from N-linked glycans, since 
the electrophoretic mobility of the protein was not affected 
by treatment with peptide:N-glycosidase F irrespective of 
prior neuraminidase digestion (Fig. 8, lanes 3 and 4). Since 
the sialylated N-linked glycans on the gelatin-binding domain 
of human plasma FN were removed with peptide:N-glycosi- 
dase F under the same conditions (data not shown), these 
results suggest that N-linked glycan is likely absent in the 
recombinant protein. In contrast, treatment of the desialy- 
lated rFib2 protein with endo-a-N-acetylgalactosaminidase, 
an enzyme that selectively removes desialylated O-linked 
glycans, resulted in a further reduction of the apparent mo- 
lecular mass of the protein (Fig. 8, lane 6). Although the same 
enzyme failed to reduce the heterogeneity of the rFib2 protein 
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FIG. 7. Limited proteolysis of the rFib2 protein. A, a sche- 
matic model for the polypeptide structure of the rFib2 protein. The 
putative cleavage sites for trypsin and thermolysin (Refs. 15, 26, 41, 
and 56-58) are indicated by arrows. Closed and open circles represent 
the putative N-linked and O-linked glycosylation sites, respectively. 
B, Immunoblot analysis of the proteolytic digests of intact cellular 
FN and the rFib2 protein. Human cellular FN (lanes 1-3) and the 
purified rFib2 protein (lanes 4-6) were digested with trypsin or 
thermolysin and then subjected to SDS-PAGE under the reducing 
condition followed by transfer of the proteins to nitrocellulose mem- 
brane. The membrane was first stained with fast green (left) and 
then immunostained with FN8-12 (center) or polyclonal anti-IIICS/ 
-1, antibodies (right). Lanes 1 and 4, control proteins; lanes 2 and 5, 
trypsin digests; lanes 3 and 6, thermolysin digests. Five rg of protein 
was applied to each lane. The positions of the tryptic 43-kDa (open 
arrowheads) and 37-kDa (closed arrowhead) fragments as well as the 
thermolysin 22-kDa fragment (arrows) are indicated. 
lane 5), this is probably due to the inability of the enzyme to 
cleave off the sialylated 0-glycans (32). 
The presence of O-linked, but absence of N-linked, glycans 
was further supported by the lectin blotting analysis (Fig. 9). 
Peanut agglutinin, a lectin that binds to desialylated O-linked 
glycans, stained the rFib2 protein only after neuraminidase 
treatment. In contrast, concanavalin A and lentil lectin, both 
of which preferentially bind to N-glycans, failed to stain the 
rFib2 protein irrespective of prior neuraminidase treatment, 
although both lectins could bind to mouse FN. The binding 
specificity of these peroxidase-conjugated lectins was con- 
firmed by inhibition of the staining with 0.2 M lactose (data 
not shown). Taken together with the results obtained using 
various proteases and glycosidases, these results indicate that 
the unexpected heterogeneity of the secreted form of the rFib2 
protein is mostly, if not totally, due to the differential sialy- 
lation of O-linked glycans localized at the IIICS region. 
P:N-GLYCOSIDASE F 






FIG. 8. Effect of glycosidase treatment on the heterogeneity 
of the rFib2 protein. The rFib2 protein was treated with neura- 
minidase, peptide:N-glycosidase F (PN-glycosidase F), endo-cu-N- 
acetylgalactosaminidase, or the combination thereof as described 
under “Experimental Procedures.” Deglycosylated proteins (5 rg) 
were analyzed by immunoblotting with FN8-12 under the reduced 
condition. The positions of the neuraminidase-treated rFib2 proteins 
with or without subsequent treatment with other glycosidases are 
pointed out by arrowheads. 
FN8-12 ConA LCA PNA 
FN- . qq q!P -r-G 
FIG. 9. Lectin-blot analysis of the rFib2 protein. The purified 
rFib2 protein (5 pg) with or without prior neuraminidase treatment 
was subjected to SDS-PAGE under the reducing condition, trans- 
ferred to nitrocellulose membrane, and then stained with either FN8- 
12 or with peroxidase-lectin conjugates. Con A, concanavalin A; LCA, 
lentil lectin; PNA, peanut agglutinin. 
DISCUSSION 
Using the DNA transfection technique, we have established 
a stably transformed mouse L cells expressing the recombi- 
nant protein consisting of the signal sequence of human 
protein C inhibitor and the Fib2 domain of human FN. The 
resulting rFib2 protein retained the ability to dimerize with 
each other or with endogenous mouse FN subunits and was 
mostly secreted to the extracellular space after an extensive 
glycosylation. Thus, the heterologous signal sequence appears 
to function properly to facilitate efficient secretion of the 
rFib2 protein. Although a significant portion of intact FNs 
synthesized by a variety of cell types has been shown to be 
incorporated in the extracellular matrix (33-35), it was found 
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protein might be deposited in the matrix upon prolonged cell 
culture. The inefficient incorporation of the recombinant 
protein is likely due to the lack of either the amino-terminal 
heparin/fibrin-binding (Hepl/Fibl) or the central cell-bind- 
ing (Cell) domain, which has been reported to be required for 
the FN matrix assembly (36, 37). Our results are consistent 
with the previous observation by Schwarzbauer et al. (18) that 
“deminectin,” the carboxyl-terminal half of rat FN expressed 
in mouse cells as a fusion protein with a heterologous signal 
sequence, was mostly secreted to the medium. 
Oligomerization of subunits of membrane and secretory 
proteins is believed to occur in the endoplasmic reticulum 
(38-40). Although little has been understood how the subunits 
of a given protein recognize each other and oligomerize 
through disulfide bonds, it is likely that certain structural 
features are generated during folding of the individual sub- 
units that allow them to recognize each other (40). Our results 
show that the Fib2 domain alone can undergo specific dimer- 
ization with one another or with endogenous mouse FN sub- 
units, suggesting that a signal for dimerization resides in the 
Fib2 domain or the extreme carboxyl-terminal segment where 
the two subunits are bridged by disultide bonds. It should be 
noted, however, that about 30% of the rFib2 protein secreted 
by the transformed cells remained undimerized (Fig. 6). Since 
the carboxyl-terminal half of rat FN expressed in mouse cells 
is secreted as homodimers or heterodimers but not as mono- 
mers (18), affinity for the intersubunit association seems to 
be reduced with the rFib2 protein described in the present 
study when compared with the longer recombinant protein or 
intact subunits. 
The rFib2 protein secreted by the transformed cells dis- 
played remarkable heterogeneity upon SDS-PAGE. Although 
the molecular mass of the processed rFib2 polypeptide is 
estimated to be 49 kDa from the cDNA sequence, the protein 
secreted to the medium gave a broad band corresponding to 
60-90 kDa under reduced conditions. Several lines of evidence 
indicate that unexpected behavior of the rFib2 protein on the 
gel is mainly due to the differential sialylation of O-linked 
glycans located at the IIICS region. First of all, the hetero- 
geneity of the rFib2 protein was mostly abolished by neura- 
minidase treatment. Sialic acid residues causing the hetero- 
geneity of the protein seems to be carried by O-linked but not 
by N-linked glycans, since peptide:N-glycosidase F treatment 
did not alter the broad banding pattern of the protein. In 
support of this conclusion, neither concanavalin A nor lentil 
lectin bound to the rFib2 protein irrespective of prior neura- 
minidase treatment, indicating that N-linked glycans are 
essentially, if not absolutely, absent in the recombinant pro- 
tein. 
In contrast, the presence of sialylated O-linked glycans was 
evidenced by the observations that (a) treatment of the desi- 
alylated rFib2 protein with endo-a-N-acetylgalactosamini- 
dase caused a small, yet significant, reduction of the apparent 
molecular mass of the protein and (b) peanut agglutinin 
specifically bound to the recombinant protein only after neur- 
aminidase treatment. Involvement of O-linked glycans in 
generating the apparent heterogeneity of the rFib2 protein 
was also proven by the observation that limited proteolysis 
with trypsin yielded an apparently homogeneous Fib2 frag- 
ment. Trypsin treatment has been shown to eliminate all of 
the O-linked glycans attached to the IIICS region (31, 41). 
Localization of the O-linked glycans at the IIICS region was 
further supported by the observation that the 43-kDa Fib2 
fragment of the rFib2 protein generated by mild trypsin 
digestion did not contain O-linked glycans detectable with 
peanut agglutinin.’ 
Despite extensive studies on the structure and localization 
of N-linked glycans of human and hamster FNs (42-45), little 
attention has been paid to the occurrence and structure of O- 
linked glycans of FNs (45, 46). Skorstengaard et al. (47) 
identified one threonine-linked glycan in the IIICS region of 
bovine plasma FN. Matsuura et al. (31) demonstrated that 
the IIICS region of human cellular FN contains five threo- 
nine-linked and one serine-linked glycans. Since each O- 
linked glycan can carry one or two sialic acid residues, up to 
12 sialic acid residues may be present in the IIICS region of 
the rFib2 protein. Thus, differential sialylation of these O- 
glycans may well explain the remarkable heterogeneity of the 
recombinant protein. 
The IIICS region of human FN mRNA has been shown to 
undergo a complex pattern of alternative RNA splicing (7, 9, 
13). Since the cDNA insert of pAISF21 contains the sequence 
encoding the IIICS/A2, one might expect that differential 
splicing of the rFib2 mRNA can generate two protein isoforms 
with and without the IIICS/A2 segment. However, tryptic 
digestion of the purified rFib2 protein revealed that only the 
isoform containing the IIICS/A2 segment was secreted from 
the transformed cells, indicating that splicing machinery of 
mouse L cells cannot splice out the 93 nucleotides encoding 
the IIICS/Az segment. Alternative splicing of FN pre-mRNA 
has been shown to be regulated in a tissue- and cell type- 
specific manner (8, 48,49). Although factors regulating alter- 
native RNA splicing has not been characterized, the L cells 
may lack the trans-acting factor(s) that recognize the partic- 
ular 93 nucleotides. Alternatively, splicing out of the 93-base 
segment may require an additional c&acting signal that is 
distal to the segment and, therefore, not included in the 
present cDNA construct. 
In striking contrast to the remarkable heterogeneity of the 
secreted form of the rFib2 protein, the proteins immunopre- 
cipitated from the detergent lysate with FN8-12 gave three 
discrete bands with M, of 51,000, 54,000, and 66,000. Unlike 
the secreted form, no heterogeneous protein band was detect- 
able with the immune precipitate from the cell lysate even 
after prolonged chase. Given the essential role of sialylation 
in generating the heterogeneity of the rFib2 protein, these 
results strongly suggest that transit of the rFib2 protein from 
cytoplasm to extracellular space requires, or is regulated by, 
sialylation of O-linked glycans. 
To date, the role of N-glycosylation in protein secretion 
and transit to plasma membrane has been extensively inves- 
tigated using a variety of N-glycosylation inhibitors (50, 51). 
It has been reported that inhibition of the processing of N- 
linked glycans by tunicamycin (52) or swainsonine (53) would 
not cause any dramatic reduction of FN secretion by cultured 
fibroblasts. Failure of these inhibitors to block transit of FN 
may well be attributable to sialylation of 0-glycans that is 
not affected by these inhibitors. Possible involvement of O- 
glycosylation in protein secretion has been implicated with 
sialomucin (54, 55). Expression of recombinant FN cDNA 
modified by site-directed mutagenesis will provide a model 
system to better understand the role of N-linked and O-linked 
glycosylation in the regulation of secretion of extracellular 
proteins. 
Acknowledgments-We thank Masahiko Katayama for kindly pro- 
viding monoclonal anti-FN antibodies and their Sepharose conju- 
gates, Drs. Akira Nagafuchi and Masatoshi Takeichi for helpful 
advice on the DNA transfection using the pBactCAT9 expression 






















Expression of a Recombinant Fibronectin Domain in Mouse Cells 407 
vector, and Dr. Masahiro Ishiura for a gift of mouse L cells and 30. 
helpful suggestions on DNA transfection. We also thank Drs. Norman 
Davidson and Koji Suzuki for providing pBactCAT9 and PCI-6mpl0, 31. 
respectively. 
Kiiimoto, S., Kataairi. Y. U., and Ochiai, H. (1985) Anal. Biochem. 
REFERENCES 32. 
1. Hynes, R. 0. (1981) in Cell Biology of Extracellular Matrix (Hay, 
33. 
E. D., ed) pp. 295-334, Plenum Publishing Corp., New York 
2. Yamada, K. M. (1983) Annu. Reu. Biochem. 52, 761-799 
34. 












CeliBiol. i, 91-113 
Mosher, D. F. (ed) (1989) Fibronectin, Academic Press, San Diego 
Gahmberg, C. G., and Hakomori, S. (1973) Proc. N&l. Acad. Sci. 
U. S. A. 70,3329-3333 
V ” .  
36. 
37. 
Hvnes. R. 0. (1973) Proc. Natl. Acad. Sci. U. S. A. 70. 3170- 
3174 
Schwarzbauer, J. E., Tamkun, J. W., Lemischka, I. R., and Hynes, 
R. 0. (1983) Cell 35.421-431 
Kornblihtt, A. R., Vibe-Pedersen, K., and Baralle, F. E. (1984) 
EMBO J. 3,221-226 
Sekiguchi. K., Klos, A. M., Kurachi, K., Yoshitake, S., and 
Hakomori, S. (1986) Biochemistry 25,4936-4941 
Zardi. L.. Carnemolla. B.. Siri. A.. Petersen. T. E.. Paolella. G.. 
Sebastio, G., and Baralie, F.E. (1987) EkBO J. 6, 2337-2342 
Gutman, A., and Kornblihtt, A. R. (1987) Proc. Natl. Acad. Sci. 
U. S. A. 84, 7179-7182 
Schwarzbauer, J. E., Patel, R. S., Fonda, D., and Hynes, R. 0. 
(1987) EMBO J. 6, 2573-2580 
Hynes, R. 0. (1985) Annu. Reu. Cell Biol. 1,67-90 
Petersen, T. E., Thegersen, H. C., Skorstengaard, K., Vibe- 
Pedersen, K., Sahl, P., Sottrup-Jensen, L., and Magnusson, S. 
(1983) Proc. Natl. Acad. Sci. U. S. A. 80, 137-141 


























Yamada, K. M. (1989) in Fibronectin (Mosher, D. F., ed) pp, 47- 
121, Academic Press, San Diego 
Ruoslahti. E. (1988) Annu. Reu. Biochem. 5’7,375-413 
Schwarzbauer, J. E., Mulligan, R. C., and Hynes, R. 0. (1987) 
Proc. Natl. Acad. Sci. U. S. A. 84. 754-758 
19. Maniatis, T.. Fritsch, E. F., and Sambrook, J. (eds) (1982) Mo- 
lecular Cloning: A Laboratory Manual, Cold Spring Harbor 








Fregien, N.,and Davidson, N. (1986) Gene (Amst.) 48, l-11 
Chen, C., and Okayama, H. (1987) Mol. Cell. Biol. 7,2745-2752 
Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, 
W. J. (1979) Biochemistry l&5294-5299 
Feinberg, A. P., and Vogelstein, B. (1983) Anal. Biochem. 132, 
6-13 
Bonner, W. M., and Laskey, R. A. (1974) Eur. J. B&hem. 46, 
83-88 
Amemiya, Y., and Miyahara, J. (1988) Nature 336,89-90 
Sekiguchi, K., and Hakomori, S. (1983) J. Biol. Chem. 258,3967- 
3973 
27. Laemmli, U. K. (1970) Nature 227,680-685 
28. Towbin. H.. Staehelin. T.. and Gordon. J. (1979) Proc. Natl. Acad. 
29. 
Sci. ii. S.‘A. 76,4350-4354 
Sekiguchi, K., and Titani, K. (1989) Biochemistry 28,3293-3298 
58. 
i47,2221229 - 
Matsuura. H.. Takio. K.. Titani. K.. Greene. T.. Leverv. S. B.. 
Salyan,‘M. E. K., and Hakomori, S: (1988) i. Biol. U&m. 263; 
3314-3322 
Endo, Y., and Kobata, A. (1976) J. Biochem. (Tokyo) 80, l-8 
Baum, J. B., McDonald, J. A., and Crystal, R. G. (1977) Biochem. 
Biophys. Res. Commun. 79,8-15 
Choi, M. G., and Hynes, R. 0. (1979) J. Biol. Chem. 254,12050- 
12055 
Carter, W. G. (1984) J. Cell Biol. 99, 105-114 
McKeown-Longo, P. J., and Mosher, D. F. (1985) J. Cell Biol. 
100,364-374 
McDonald, J. A., Quade, B. J., Broekelmann, T. J., LaChance, 
R., Forsman, K., Hasegawa, E., and Akiyama, S. (1987) J. Biol. 
Chem. 262,2957-2967 
Gething, M. J., McCammon, K., and Sambrook, J. (1986) Cell 
46,939-950 
Bole, D. G., Hendershott, L. M., and Kearney, J. F. (1986) J. Cell 
Biol. 102, 1558-1566 
Rose, J. K., and Doms, R. W. (1988) Annu. Reu. Cell Biol. 4,257- 
288 
Garcia-Pardo, A., Pearlstein, E., and Frangione, B. (1985) J. Biol. 
Chem. 260,10320-10325 
Sekiauchi. K.. and Hakomori. S. (1980) Proc. Natl. Acad. Sci. U. 
S.2. 7i, 2661-2665 
Fukuda, M., Levery, S. B., and Hakomori, S. (1982) J. Biol. Chem. 
257.6856-6860 
Murayama, K., Nichols, E. J., Levery, S. B., Carter, W. G., and 
Hakomori. S. (1984) GlvcoconiuPate J. 1.155-169 
Nichols, E. J., Fenderson, B. A., Carter, W. G., and Hakomori, 
S. (1986) J. Biol. Chem. 261,11295-11301 
Krusius, T., Fukuda, M., Dell, A., and Ruoslahti, E. (1985) J. 
Biol. Chem. 260,4110-4116 
Skorstensgaard. K., Jensen, M. S., Sahl, P., Petersen, T. E., and 
Magnusson, S. (1986). Eur. J. Biochem. 161,441-453 
Paul, J. I., Schwarzbauer, J. E., Tamkun, J. W., and Hynes, R. 
0. (1986) J. Biol. Chem. 261,12258-12265 
Ovama. F.. Murata. Y.. Sueanuma. N.. Kimura. T.. Titani. K.. 
“and Sekiguchi, K: (1989) Biochemist& 28,1428-1434 
Olden, K., Parent, J. B., and White, S. L. (1982) Biochim. 
Biophys. Acta 650,209-232 
Elbein, A. D. (1987) Annu. Reu. Biochem. 56.497-534 
Olden, K., Pratt, R. M., and Yamada, K. M. (1978) Cell 13,461- 
473 
Arumugham, R. G., and Tanzer, M. L. (1983) J. Biol. Chem. 258, 
11883-11889 
Spielman, J., Rockley, N. L., and Carraway, K. L. (1987) J. Biol. 
Chem. 262,269-275 
Spielman, J., Hull, S. R., Sheng, Z., Kanterman, R., Bright, A., 
and Carraway, K. L. (1988) J. Biol. Chem. 263,9621-9629 
Garcia-Pardo, A., Pearlstein, E., and Frangione, B. (1984) 
Biochem. Biophys. Res. Commun. 120, 1015~1021 
Pande. H.. Calavcav, J., Lee, T. D., Legesse, K., Shivelv, J. E., 
Siri, A., Borsi; L.; and Zardi, L. (1987i Eur. J.~Biochem. 162; 
403-411 























K Ichihara-Tanaka, K Titani and K Sekiguchi
expressed in mouse L cells.
Recombinant carboxyl-terminal fibrin-binding domain of human fibronectin
1990, 265:401-407.J. Biol. Chem. 
  
 http://www.jbc.org/content/265/1/401Access the most updated version of this article at 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/265/1/401.full.html#ref-list-1
This article cites 0 references, 0 of which can be accessed free at
 at O
SA
K
A
 U
N
IV
E
R
SIT
Y
 on M
arch 7, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
